Specifically, We validated earlier findings of increased IgG secretion against the C-terminal portion of EBNA1 in MS patients (27, 34, 41, 42) in vitro and confirmed that these correlated well with the serum titers of anti-EBNA1 in HDs and NAT patients. This evidence concerns the gene BRD2 and myeloid sarcoma.